ASCA across ethnic groups

What is known

• In one cohort ASCA had 37% sensitivity and 97% specificity for CD, and a positive test made inflammatory disease, most likely CD, nearly 40-fold more likely. ¹
• In a Scottish cohort ASCA was present in 57% of CD, 19% of UC, 30% of indeterminate colitis, and 8% of healthy controls (sensitivity 57%, specificity 87%, PPV 78%). ²
• Reported ASCA accuracy for CD ranges roughly from 46–60% sensitivity and 88–95% specificity, and one study hypothesized this wide range relates to ethnicity and racial diversity. ³
• ASCA-positive results occurred not only in CD but also in ulcerative colitis, indeterminate colitis, celiac disease, and a patient with no disease. ^1,2

What is unknown / caveats

• Reported ASCA sensitivity/specificity ranges vary widely across studies (CD sensitivity ~46–60%, specificity ~88–97%)
• One study argues variability may reflect ethnicity/race; direct cross-ethnic performance data were not provided in the excerpts
• Excerpts do not provide direct head-to-head ASCA performance data across specific ethnic groups; the ethnicity effect is hypothesized, and one study deliberately used a homogeneous population to avoid it
• Cohorts are drawn from single regions (Manitoba, Scotland, West Virginia, Morocco), limiting generalizability
• ASCA in isolation is described as not clinically useful for distinguishing CD, UC and IC; combining with pANCA/other markers is suggested
• The excerpts note that ethnicity/race may explain the variable ASCA performance but do not directly quantify how accuracy differs between specific ethnic groups.

References

1. Kaila B, Orr K, Bernstein CN. The anti-Saccharomyces cerevisiae antibody assay in a province-wide practice: accurate in identifying cases of Crohn's disease and predicting inflammatory disease. Can J Gastroenterol. 2005;19(12):717-21. PMID: 16341311.

2. Walker LJ, Aldhous MC, Drummond HE, Smith BR, Nimmo ER, Arnott ID, Satsangi J. Anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn's disease are associated with disease severity but not NOD2/CARD15 mutations. Clin Exp Immunol. 2004;135(3):490-6. PMID: 15008984.

3. Elitsur Y, Lawrence Z, Tolaymat N. The diagnostic accuracy of serologic markers in children with IBD: the West Virginia experience. J Clin Gastroenterol. 2005;39(8):670-3. PMID: 16082274.

For educational use only, not a substitute for clinical judgement or medical advice. Consult qualified clinicians for diagnosis and treatment decisions. This tool may contain errors; use the flag button below to report inaccurate or harmful content.

Draft, generated by the IBDology RAG and not yet clinician-reviewed. Answers are grounded in the retrieved literature listed above; a high faithfulness score means the answer matches its sources, not that the sources are correct.